A method for increasing the number of directional differentiation of umbilical cord blood megakaryotic progenitor cells

A technology for megakaryotic progenitor cells and directed differentiation, which is applied in the field of increasing the number of directed differentiation of umbilical cord blood hematopoietic stem cells to megakaryotic progenitor cells, can solve problems such as increased cost, pollution, and adverse effects on in vitro amplification efficiency, and achieves the goal of increasing the number of directed differentiation, The effect of high safety and less toxic effects
CN104789530BActive Publication Date: 2017-10-13广州市天河诺亚生物工程有限公司
4 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
广州市天河诺亚生物工程有限公司
Publication Date
2017-10-13

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a method for increasing the number of directional differentiation of umbilical cord blood megakaryocyte progenitor cells. In this method, umbilical cord blood hematopoietic stem cells are used as sample cells, and directed differentiation is carried out in a specific medium containing resveratrol. The specific medium containing resveratrol makes the operation of directed differentiation of megakaryotic progenitor cells easier, safer and more efficient. In the process of directional differentiation and culture of umbilical cord blood hematopoietic stem cells to megakaryotic progenitor cells, resveratrol is added together with cytokines to achieve the effect of increasing the number of megakaryotic progenitor cells. The method of the present invention is easy to operate and low in cost. Cell safety is high.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of cell technology, and in particular relates to a method for increasing the number of directed differentiation of umbilical cord blood hematopoietic stem cells to megakaryotic progenitor cells. Background technique

[0002] Hematopoietic stem cells have the ability to self-renew and differentiate into precursor cells of various blood cells, which eventually form blood cells, including red blood cells, white blood cells and platelets. Hematopoietic stem cells are mainly derived from bone marrow, umbilical cord blood and peripheral blood, and are clinically used for transplantation to treat various malignant blood diseases and certain immune diseases.

[0003] In 1989, the first case of umbilical cord blood transplantation was successful. So far, umbilical cord blood transplantation / transfusion has become an important clinical treatment for blood system diseases and certain immune diseases. Like bone marrow hematopoie...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More